United Therapeutics Corporation Deferred Income Tax Assets, Net
United Therapeutics Corporation (UTHR) had Deferred Income Tax Assets, Net of $311.60 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:DeferredIncomeTaxAssetsNet · last filed 2026-08-05
- 2026-06-30: Deferred Income Tax Assets, Net $311.60M.
- 2026-03-31: Deferred Income Tax Assets, Net $335.40M.
- 2025-12-31: Deferred Income Tax Assets, Net $357.70M.
- 2025-09-30: Deferred Income Tax Assets, Net $354.90M.
| Period end | Deferred Income Tax Assets, Net |
|---|---|
| 2026-06-30 | $311.60M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $335.40M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $357.70M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $354.90M 10-Q · filed 2025-10-29 |
| 2025-06-30 | $456.20M 10-Q · filed 2025-07-30 |
| 2025-03-31 | $456.60M 10-Q · filed 2025-04-30 |
| 2024-12-31 | $458.40M 10-K · filed 2026-02-25 |
| 2024-09-30 | $390.90M 10-Q · filed 2024-10-30 |
| 2024-06-30 | $395.60M 10-Q · filed 2024-07-31 |
| 2024-03-31 | $396.10M 10-Q · filed 2024-05-01 |
| 2023-12-31 | $394.80M 10-K · filed 2025-02-26 |
| 2023-09-30 | $325.60M 10-Q · filed 2023-11-01 |
| 2023-06-30 | $325.60M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $321.90M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $327.70M 10-K · filed 2024-02-21 |
| 2022-09-30 | $281.30M 10-Q · filed 2022-11-02 |
| 2022-06-30 | $275.30M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $271.80M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $261.90M 10-K · filed 2023-02-22 |
| 2021-09-30 | $273.90M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $264.20M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $263.60M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $238.60M 10-K · filed 2022-02-24 |
| 2020-09-30 | $255.50M 10-Q · filed 2020-10-28 |
| 2020-06-30 | $245.80M 10-Q · filed 2020-07-29 |
| 2020-03-31 | $246.10M 10-Q · filed 2020-04-29 |
| 2019-12-31 | $230.00M 10-K · filed 2021-02-24 |
| 2018-12-31 | $95.70M 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |